Is Your Own Collagen Secretly Fueling Diabetes In You? IIT Study Uncovers Startling New Link
Scientists at IIT Bombay have found collagen protein helps form harmful hormone clumps in the pancreas, advancing understanding and opening doors to new diabetes treatments
Diabetes is increasingly becoming a global health concern, with experts warning it may reach epidemic proportions in the coming decades. The disease primarily manifests in two forms: Type 1, an autoimmune condition with genetic links, and Type 2, whose precise causes remain largely unknown.
In a groundbreaking study, researchers at IIT Bombay have uncovered a surprising connection between collagen, the body's most abundant structural protein, and the progression of Type 2 diabetes. Collagen appears to promote the accumulation of a hormone called amylin within the pancreas, impairing its function by reducing insulin production and thereby elevating blood sugar levels.
The study, published in the Journal of the American Chemical Society, explains that alongside insulin, the body produces amylin to regulate blood sugar after meals. However, abnormal amylin can clump together as amyloid aggregates, damaging pancreatic beta cells and worsening diabetes.
Professor Shamik Sen and his team revealed that fibrillar collagen 1 encourages the formation of these harmful clumps, increasing the risk of Type 2 diabetes. This new insight highlights the crucial role of structural proteins in diabetes development, beyond just blood sugar levels.
These findings could lead to innovative treatments aimed at restoring pancreatic health by managing collagen and amylin levels, offering fresh hope to millions affected by Type 2 diabetes.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Print
3 days ago
- The Print
Delhi HC asks DGCI to decide representation over weight-loss drugs
A plea filed by Jitendra Chouksey said licenses issued for the use and sale of such drugs were not based on adequate data. A bench of Chief Justice D K Upadhyaya and Justice Tushar Rao Gedela asked the petitioner to give a representation to the DGCI, which was asked to decide the matter within three months. New Delhi, Jul 2 (PTI) The Delhi High Court on Wednesday asked the Drug Controller General of India to consult experts and relevant stakeholders in deciding a plea over drug combinations sold in the market for weight loss treatment. In an apparent reference to the recent death of popular TV actor Shefali Jariwala, the court said, 'See what happened two-three days back…' News reports suggest Jariwala was taking anti-ageing treatment for the last several years. The petitioner claimed the licenses have been issued without conducting any specific trials and studies and without noting the serious adverse health effects of the drugs. 'These drugs were originally developed and internationally approved for the treatment of Type 2 Diabetes Mellitus, with their primary therapeutic role being the regulation of glycemic levels. However, over the past few years, they have been repurposed and approved often through accelerated pathways for obesity treatment and chronic weight management, based largely on short-term efficacy trials,' the plea said. It said under the Drugs and Cosmetics Act, it is the DCGI which is the competent and statutory authority entrusted with taking appropriate measures to ensure safe use of drugs. The petitioner said representations were made on April 18 to the Centre and DCGI on the issue. The court, however, said the plea's concerns have to be first looked into and addressed by the DCGI as it allowed the petitioner to move the authority by way of an additional representation and bring relevant material and documents to its notice. The additional representation was directed to be submitted to the DGCI within a fortnight. 'In case such an additional representation is preferred enclosing all the documents and material necessary for addressing the issue raised in the writ petition, the same shall be attended to and considered appropriately and as per law by the authority concerned,' the court said. The order added, 'DCGI shall consult experts as also other stakeholders such as manufacturers of the drugs in question.' PTI SKV SKV AMK AMK This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.
The Hindu
3 days ago
- The Hindu
Delhi High Court asks DGCI to decide on plea against licensing of weight-loss drugs
The Delhi High Court asked the Drug Controller General of India (DCGI) on Wednesday (July 2, 2025) to consult experts and relevant stakeholders in deciding a plea over drug combinations sold in the market for weight-loss treatment. A bench of Chief Justice D. K. Upadhyaya and Justice Tushar Rao Gedela asked the petitioner, Jitendra Chouksey, to give a representation to the DGCI, which was asked to decide the matter within three months. Mr. Chouksey, in his plea, alleged licenses issued for the use and sale of such drugs were not based on adequate data. The court, however, said the plea's concerns have to be first looked into and addressed by the DCGI. It allowed Mr. Chouksey to move the authority and bring relevant material and documents to its notice. Lack of clinical trials The plea raised concerns regarding the manner in which 'Glucagon-like peptide-1 receptor agonist (RA) drugs, specifically semaglutide, tirzepatide, and liraglutide, have been granted marketing approval in India for use in weight management and aesthetic treatments, despite limited safety data, lack of India-specific clinical trials, and absence of a robust pharmacovigilance or regulatory oversight mechanism.' It claimed that 'numerous studies have further highlighted the significant risks posed by these medications, including pancreatitis, gastrointestinal damage, thyroid and pancreatic cancers, cardiovascular complications, metabolic dysregulation, and optic neuropathy.' The plea said these drugs were originally developed and internationally approved for the treatment of Type 2 Diabetes Mellitus, with their primary therapeutic role being the regulation of glycemic levels. 'However, over the past few years, they have been repurposed and approved often through accelerated pathways for obesity treatment and chronic weight management, based largely on short-term efficacy trials,' it added. The plea said, 'In India, the CDSCO (Central Drugs Standard Control Organisation) has recently approved these drugs for weight- loss purposes without requiring large-scale clinical trials specific to Indian demographics or mandating post-marketing surveillance.' Mr. Chouksey said there is no evidence to suggest that these drugs have undergone rigorous safety evaluation within the Indian population. He cautioned that pharmaceutical companies, clinics, and digital wellness platforms are promoting the drug combinations as 'quick-fix' weight-loss solutions.
News18
3 days ago
- News18
Is Your Own Collagen Secretly Fueling Diabetes In You? IIT Study Uncovers Startling New Link
Last Updated: Scientists at IIT Bombay have found collagen protein helps form harmful hormone clumps in the pancreas, advancing understanding and opening doors to new diabetes treatments Diabetes is increasingly becoming a global health concern, with experts warning it may reach epidemic proportions in the coming decades. The disease primarily manifests in two forms: Type 1, an autoimmune condition with genetic links, and Type 2, whose precise causes remain largely unknown. In a groundbreaking study, researchers at IIT Bombay have uncovered a surprising connection between collagen, the body's most abundant structural protein, and the progression of Type 2 diabetes. Collagen appears to promote the accumulation of a hormone called amylin within the pancreas, impairing its function by reducing insulin production and thereby elevating blood sugar levels. The study, published in the Journal of the American Chemical Society, explains that alongside insulin, the body produces amylin to regulate blood sugar after meals. However, abnormal amylin can clump together as amyloid aggregates, damaging pancreatic beta cells and worsening diabetes. Professor Shamik Sen and his team revealed that fibrillar collagen 1 encourages the formation of these harmful clumps, increasing the risk of Type 2 diabetes. This new insight highlights the crucial role of structural proteins in diabetes development, beyond just blood sugar levels. These findings could lead to innovative treatments aimed at restoring pancreatic health by managing collagen and amylin levels, offering fresh hope to millions affected by Type 2 diabetes.
